发布求助
文献互助 智能选刊 最新文献

Cardiac Failure Review最新文献

筛选
英文 中文
CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report. 基于钆造影剂的心脏ems植入:1例报告。
Cardiac Failure Review Pub Date : 2021-04-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.03
Aniket S Rali, Lynne W Stevenson, Sandip K Zalawadiya
{"title":"CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report.","authors":"Aniket S Rali,&nbsp;Lynne W Stevenson,&nbsp;Sandip K Zalawadiya","doi":"10.15420/cfr.2021.03","DOIUrl":"https://doi.org/10.15420/cfr.2021.03","url":null,"abstract":"<p><p>A 57-year-old woman with New York Heart Association Class III heart failure requiring multiple hospitalisations over the previous year presented for CardioMEMS implantation. Because of the patient's allergy history of anaphylaxis to iodine-based contrast agent she underwent the device implantation with gadolinium-based contrast agent (Magnevist), which was successful.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2021-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/d5/cfr-07-e07.PMC8076965.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38950467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. 舒比利/缬沙坦在心力衰竭和射血分数降低患者治疗过程中的基本原理和实际应用
Cardiac Failure Review Pub Date : 2021-04-05 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.25
Mauro Gori, James L Januzzi, Emilia D'Elia, Ferdinando L Lorini, Michele Senni
{"title":"Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction.","authors":"Mauro Gori,&nbsp;James L Januzzi,&nbsp;Emilia D'Elia,&nbsp;Ferdinando L Lorini,&nbsp;Michele Senni","doi":"10.15420/cfr.2020.25","DOIUrl":"https://doi.org/10.15420/cfr.2020.25","url":null,"abstract":"<p><p>Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade. Contemporary data suggest that sacubitril/valsartan is associated with improved outcomes compared with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and has a greater beneficial effect on myocardial reverse remodelling. Additionally, two recent trials have shown that sacubitril/valsartan is well-tolerated even in the acute HF setting, thus enabling a continuum of use in the patient's journey with HFrEF. This article summarises available data on the effectiveness and tolerability of sacubitril/valsartan in patients with HFrEF, and provides the clinician with practical insights to facilitate the use of this drug in every setting, with an emphasis on acute HF, hypotension, electrolyte imbalance and renal insufficiency.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e06"},"PeriodicalIF":0.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/12/cfr-07-e06.PMC8054374.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38900264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Representation of Women Physicians in Heart Failure Clinical Practice. 女性医生在心力衰竭临床实践中的代表性。
Cardiac Failure Review Pub Date : 2021-03-31 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.31
Ersilia M DeFilippis, Yasbanoo Moayedi, Nosheen Reza
{"title":"Representation of Women Physicians in Heart Failure Clinical Practice.","authors":"Ersilia M DeFilippis,&nbsp;Yasbanoo Moayedi,&nbsp;Nosheen Reza","doi":"10.15420/cfr.2020.31","DOIUrl":"https://doi.org/10.15420/cfr.2020.31","url":null,"abstract":"<p><p>Women have been integral in the development of advanced heart failure (HF) and transplantation as a clinical subspecialty of cardiovascular medicine. However, women remain underrepresented in leadership positions, senior academic ranks and as researchers in HF. In recent years, there have been accelerating efforts to examine sex differences in the clinical and research domains of HF. The purpose of this review is to discuss the representation of women in HF training programmes and clinical practice, the demographics of HF clinicians compared with other cardiology subspecialties, the persistent sex disparities in HF practice and research environments and potential strategies to promote equity and inclusion for women in the field.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e05"},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/bc/cfr-07-e05.PMC8054365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38900263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. 新型抗糖尿病药物试验的心血管结局。
Cardiac Failure Review Pub Date : 2021-03-05 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.19
Chris Wai Hang Lo, Yue Fei, Bernard Man Yung Cheung
{"title":"Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes.","authors":"Chris Wai Hang Lo,&nbsp;Yue Fei,&nbsp;Bernard Man Yung Cheung","doi":"10.15420/cfr.2020.19","DOIUrl":"https://doi.org/10.15420/cfr.2020.19","url":null,"abstract":"<p><p>Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e04"},"PeriodicalIF":0.0,"publicationDate":"2021-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/30/cfr-07-e04.PMC7970669.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25501362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Viscoelastic Haemostatic Assays in Cardiovascular Critical Care. 心血管危重症的粘弹性止血试验。
Cardiac Failure Review Pub Date : 2021-02-19 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.22
Aniket S Rali, Ahmed M Salem, Melat Gebre, Taylor M Garies, Siva Taduru, Arthur W Bracey
{"title":"Viscoelastic Haemostatic Assays in Cardiovascular Critical Care.","authors":"Aniket S Rali,&nbsp;Ahmed M Salem,&nbsp;Melat Gebre,&nbsp;Taylor M Garies,&nbsp;Siva Taduru,&nbsp;Arthur W Bracey","doi":"10.15420/cfr.2020.22","DOIUrl":"https://doi.org/10.15420/cfr.2020.22","url":null,"abstract":"<p><p>The initiation and management of anticoagulation is a fundamental practice for a wide variety of indications in cardiovascular critical care, including the management of patients with acute MI, stroke prevention in patients with AF or mechanical valves, as well as the prevention of device thrombosis and thromboembolic events with the use of mechanical circulatory support and ventricular assist devices. The frequent use of antiplatelet and anticoagulation therapy, in addition to the presence of concomitant conditions that may lead to a propensity to bleed, such as renal and liver dysfunction, present unique challenges. The use of viscoelastic haemostatic assays provides an additional tool allowing clinicians to strike a delicate balance of attaining adequate anticoagulation while minimising the risk of bleeding complications. In this review, the authors discuss the role that viscoelastic haemostatic assay plays in cardiac populations (including cardiac surgery, heart transplantation, extracorporeal membrane oxygenation, acute coronary syndrome and left ventricular assist devices), and identify areas in need of further study.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e01"},"PeriodicalIF":0.0,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/ec/cfr-07-e01.PMC7919676.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25467261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes? 新发心力衰竭和急性失代偿慢性心力衰竭的临床特征：它们是导致不同结果的独特表型吗？
IF 4.2
Cardiac Failure Review Pub Date : 2021-02-19 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.20
Wilson Matthew Raffaello, Joshua Henrina, Ian Huang, Michael Anthonius Lim, Leonardo Paskah Suciadi, Bambang Budi Siswanto, Raymond Pranata
{"title":"Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?","authors":"Wilson Matthew Raffaello, Joshua Henrina, Ian Huang, Michael Anthonius Lim, Leonardo Paskah Suciadi, Bambang Budi Siswanto, Raymond Pranata","doi":"10.15420/cfr.2020.20","DOIUrl":"10.15420/cfr.2020.20","url":null,"abstract":"<p><p>Heart failure is currently one of the leading causes of morbidity and mortality. Patients with heart failure often present with acute symptoms and may have a poor prognosis. Recent evidence shows differences in clinical characteristics and outcomes between de novo heart failure (DNHF) and acute decompensated chronic heart failure (ADCHF). Based on a better understanding of the distinct pathophysiology of these two conditions, new strategies may be considered to treat heart failure patients and improve outcomes. In this review, the authors elaborate distinctions regarding the clinical characteristics and outcomes of DNHF and ADCHF and their respective pathophysiology. Future clinical trials of therapies should address the potentially different phenotypes between DNHF and ADCHF if meaningful discoveries are to be made.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e02"},"PeriodicalIF":4.2,"publicationDate":"2021-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/96/cfr-07-e02.PMC7919682.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25467263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary Embolism and Heart Failure: A Reappraisal. 肺栓塞和心力衰竭:重新评估。
Cardiac Failure Review Pub Date : 2021-02-18 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.26
Mattia Arrigo, Lars Christian Huber
{"title":"Pulmonary Embolism and Heart Failure: A Reappraisal.","authors":"Mattia Arrigo,&nbsp;Lars Christian Huber","doi":"10.15420/cfr.2020.26","DOIUrl":"https://doi.org/10.15420/cfr.2020.26","url":null,"abstract":"<p><p>Acute heart failure and acute pulmonary embolism share many features, including epidemiological aspects, clinical presentation, risk factors and pathobiological mechanisms. As such, it is not surprising that diagnosis and management of these common conditions might be challenging for the treating physician, in particular when both are concomitantly present. While helpful guidelines have been elaborated for both acute heart failure and pulmonary embolism, not many studies have been published on the coexistence of these diseases. With a special focus on diagnostic tools and therapeutic options, the authors review the available literature and, when evidence is lacking, present their own approach to the management of dyspnoeic patients with acute heart failure and pulmonary embolism.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e03"},"PeriodicalIF":0.0,"publicationDate":"2021-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/80/cfr-07-e03.PMC7926477.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25467264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Acute Heart Failure in Coronavirus Disease 2019 and the Management of Comedications. 2019冠状病毒病急性心力衰竭及药物管理
Cardiac Failure Review Pub Date : 2020-11-23 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.24
Chia Siang Kow, Syed Shahzad Hasan
{"title":"Acute Heart Failure in Coronavirus Disease 2019 and the Management of Comedications.","authors":"Chia Siang Kow,&nbsp;Syed Shahzad Hasan","doi":"10.15420/cfr.2020.24","DOIUrl":"https://doi.org/10.15420/cfr.2020.24","url":null,"abstract":"","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e32"},"PeriodicalIF":0.0,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/76/cfr-06-e32.PMC7851738.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25343645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. 钠-葡萄糖共转运蛋白2抑制剂在心力衰竭中的应用:最新数据和实践意义。
Cardiac Failure Review Pub Date : 2020-11-13 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.23
Giuseppe Rosano, David Quek, Felipe Martínez
{"title":"Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice.","authors":"Giuseppe Rosano,&nbsp;David Quek,&nbsp;Felipe Martínez","doi":"10.15420/cfr.2020.23","DOIUrl":"https://doi.org/10.15420/cfr.2020.23","url":null,"abstract":"<p><p>Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium.glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary hospitalisation due to heart failure and cardiovascular death in these patients. Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have demonstrated the positive clinical impact of SGLT2 inhibition in patients with heart failure with reduced ejection fraction both with and without T2D. These data have led to the approval of dapagliflozin for the treatment of patients with heart failure with reduced ejection fraction, irrespective of T2D status. This article reviews the latest data reported from the DAPA-HF and EMPEROR-Reduced trials and their clinical implications for the treatment of patients with heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e31"},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/87/cfr-06-e31.PMC7689869.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38688925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Corrigendum to: Pulmonary Hypertension in Heart Failure Patients. 心力衰竭患者肺动脉高压的勘误表。
Cardiac Failure Review Pub Date : 2020-10-23 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.1.1
Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek
{"title":"Corrigendum to: Pulmonary Hypertension in Heart Failure Patients.","authors":"Sriram D Rao,&nbsp;Srinath Adusumalli,&nbsp;Jeremy A Mazurek","doi":"10.15420/cfr.2020.1.1","DOIUrl":"https://doi.org/10.15420/cfr.2020.1.1","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.15420/cfr.2019.09.].</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e30"},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/16/cfr-06-e30.PMC7607380.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38571028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信